Hostname: page-component-7479d7b7d-q6k6v Total loading time: 0 Render date: 2024-07-11T23:56:17.008Z Has data issue: false hasContentIssue false
  • English
  • Français

Induction of yawning by low doses of apomorphine (0.1, 0.2 and 0.4 mg) in healthy volunteers

Published online by Cambridge University Press:  28 April 2020

O. Blin ,
P. Danjou ,
D. Warot ,
J. Fondarai  and
A.J. Puech
O. Blin
Affiliation:
Clinique des Maladies Neuromusculaires, CHU Timone, 13005, Marseille
P. Danjou*
Affiliation:
Département de Pharmacologie Clinique, Hôpital de la Pitié-Salpêtrière, 47 Bd de l‘Hôpital, 75651Paris Cedex 13
D. Warot
Affiliation:
Département de Pharmacologie Clinique, Hôpital de la Pitié-Salpêtrière, 47 Bd de l‘Hôpital, 75651Paris Cedex 13
J. Fondarai
Affiliation:
Service de Statistique, ERACM, 232 Bd Ste-Marguerite, 13009Marseille, France
A.J. Puech
Affiliation:
Département de Pharmacologie Clinique, Hôpital de la Pitié-Salpêtrière, 47 Bd de l‘Hôpital, 75651Paris Cedex 13
*
*Correspondance and reprints
Get access

Summary

The dopaminergic agonist apomorphine hydrochloride (0.1, 0.2 and 0.4 mg s.c.) compared to placebo in a double-blind, latin square design induced yawing in population of 8 healthy volunteers. Yawning was the only behavioral effect observed and was not dose-related, as all the 3 doses were equipotent. Yawning was maximum between 10 and 20 min post-injection and did not last longer than 20 min. Compared to the data in the literature, 0.1 mg is the lowest dose described as inducing yawning in man. Further studies using doses lower than 0.1 mg would be required to determine the highest inactive dose in order to use apomorphine-induced yawning as an index of CNS dopaminergic receptor sensitivity.

Résumé

Résumé

L'apomorphine, agoniste dopaminergique, administrée en sous-cutané à la dose de 0.1, 0.2 et 0.4 mg s.c., a entra— Baillements induits chez le volontaire sain par de faibles doses d’apomorphinené des baillements chez 8 volontaires sains, comparativement au placebo. Les baillements ont été les seuls effets comportementaux observés. Il n’existe pas de relation dose-effet aux trois doses étudiees mais les trois traitements sont differents du placebo entre la 10e et la 20e minute aprés l’injection. Des doses plus faibles seraient donc à étudier de maniére à se situer dans la zone de linéarité de la relation dose-effet, pour l’évaluation ultérieure de la sensibilité des systémes dopaminergiques centraux.

Keywords

apomorphineyawninghealthy volunteerdopamineapomorphinebaillementsvolontaires sainsdopamine
Type
Original article
Information
Psychiatry and Psychobiology , Volume 3 , Issue 3 , 1988 , pp. 195 - 199
Copyright
Copyright © European Psychiatric Association 1988

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Anias, J.Holmgren, B.Urba-Holmgren, R. & Eguibar, J.R. (1984) Circadian variation of yawning behavior. Acta Neurobiol. Exp. (Warsaw) 44, 179–186Google ScholarPubMed
Corsini, G.U.Piccardi, M.P.Bochetta, A.Bernardi, F. & Del, Zompo M. (1981) Behavioural effects of apomorphine in man: Dopamine reccptor implications.In: Apomorphine and other Dopaminomimetics (Corsini, G.U. & Gessa, G.L., eds.), Raven Press, New YorkGoogle Scholar
Costentin, J.Dubuc, I. & Protais, P. (1983) Behavioural data suggesting the plurality of central dopamine receptors. CNS Receptors.In: Molecular Pharmacology to Behavior (Mandel, P. & Defreudis, H., eds.), Raven Press, New York, pp. 289–297Google Scholar
Dourish, C.T.Cooper, S.J. & Philip, S.R. (1985a) Yawning elicited by systemic and intrastriatal injection of piribedil and apomorphine in the rat. Psychopharmacology 86, 175–181CrossRefGoogle Scholar
Dourish, C.T. & Hutson, P.H. (1985b) Bilateral lesions of the striatum induced with 6-hydroxydopamine abolish apomorphine-induced yawning in rats. Neuropharmacology 24, 1051–1055CrossRefGoogle Scholar
Dubuc, I., Protais, P., Colboc, O. & Costentin, J. (1982) Antagonism of the apomorphine induced yawning by “ atypical” neuroleptics. Neuropharmacology 21, 1203–1206CrossRefGoogle ScholarPubMed
Ernst, A.M. (1967) Mode of action of apomorphine and dexamphetamine on gnawing compulsion in rats. Psychopharmacology 10, 316–323CrossRefGoogle ScholarPubMed
Gower, A.J.Berendsen, H.H.G.Princen, M.M. & Broekkamp, C.L. (1984) The yawning penile erection syndrome as a model for putative dopamine autoreceptor activity. Eur. J. Pharmacol. 103, 81–89CrossRefGoogle ScholarPubMed
Heusner, A.P. (1946) Yawning and associated phenomena. Physiol. Rev. 26, 156–168CrossRefGoogle ScholarPubMed
Hindmarch, I. & Gudgeon, A.C. (1980) The effects of clobazam and lorazepam on aspects of psychomotor performances and car handling ability. Br. J. Clin. Pharmacol. 10, 145–150CrossRefGoogle ScholarPubMed
Holmgren, B.Urba-Holmgren, R.Trucios, N.Zermeno, M. & Eguibar, J.R. (1985) Association of spontaneous and dopaminergic induced yawning and penile erections in the rats. Pharmacol. Biochem. Behav. 22, 31–35CrossRefGoogle Scholar
Lal, S.Nair, N.P.V.Iskandar, H.I.Etienne, P.Wood, P.L.Schwartz, G. & Guyda, H. (1982) Effect of domperidone on apomorphine-induced growth hormone secretion in normal men. J. Neural Transm. 54, 75–84CrossRefGoogle ScholarPubMed
Lal, S.Grassino, A.Thavundayil, J.X. & Dubrovsky, B. (1987) A simple method for the study of yawning in man induced by the dopamine agonist apomorphine. Prog. Neuropsychopharmacol. & Biol. Psychiatry 11, 223–228CrossRefGoogle Scholar
Mogilnicka, E. & Klimek, V. (1977) Drugs affecting dopamine neurons and yawning behavior. Pharmacol. Biochem. Behav. 7, 303—305CrossRefGoogle ScholarPubMed
Mogilnicka, E.Boissard, C.G. & Delini-Stula, A. (1984) Effects of apomorphine, TL 99 and 3-PPP on yawning in rats. Neuropharmacology 23, 19–22CrossRefGoogle ScholarPubMed
Morelli, M.Longoni, R.Spina, L. & Di, Chiara G. (1986) Antagonism of apomorphine induced yawning by SCH 23390: evidence against the autoreceptor hypothesis. Psychopharmacology 89, 259–260CrossRefGoogle ScholarPubMed
Nair, N.P.V.Lal, S.Thavundayil, J.W.Wood, P.L.Etienne, P. & Guyda, H. (1984) CCK-33 antagonizes apomorphine-induced growth hormone secretion and increases basal prolaetin levels in man. Neuropeptides 4, 281–291CrossRefGoogle ScholarPubMed
Nickolson, V.J. & Berendsen, H.H.G. (1980) Effects of the potential neuroleptic peptide DES-tyrosine-gamma endorphin and haloperidol on apomorphine-induced behavioural syndromes in rats and mice. Life Sci. 27, 1377–1385CrossRefGoogle ScholarPubMed
Okuyama, S.Shimamura, H.Hashimoto, S. & Aihara, H. (1986) Electrophysiological and behavioral assessments of dopamine autoreceptor activation to apomorphine in rats. Arch. Int. Pharmacodyn. Ther. 284, 246–254Google ScholarPubMed
Puech, A.J.Simon, P.Chermat, R. & Boissier, Y. (1974) Profil neuropsychologique de l’apomorphine. J. Pharmacol. 5, 241–254Google Scholar
Serra, G.Collu, M. & Gessa, G.L. (1987) Yawning is elicited by D2 dopamine agonists but is blocked by the DI antagonist, SCH 23390. Psychopharmacology 91, 330–333CrossRefGoogle Scholar
Stahle, L. & Ungerstedt, U. (1984) Assessment of dopamine autoreceptor properties of apomorphine and ( +)-3-PPP and (-)-3-PPP by recording yawning behavior in rats. Eur. J. Pharmacol. 98, 307–310CrossRefGoogle ScholarPubMed
Szechtman, H. (1984) Timing of yawns induced by small doses of apomorphine and its alteration by naloxone. Prog. NeuropsychopharmacoL Biol. & Psychiatry 8, 743–746CrossRefGoogle Scholar
Ushijima, I.Mizuki, Y.Yamada, M.Noda, Y.Yamada, K. & Furukawa, T. (1985) Characteristics of yawning behavior induced by apomorphine, physostigmine and pilocarpine. Arch. Int. Pharmacodyn. Ther. 273, 196–201Google ScholarPubMed
Yamada, K. & Furukawa, T. (1980) Direct evidence for involvement of dopaminergic inhibition and cholinergic activation in yawning. Psychopharmacology 67, 39–43CrossRefGoogle ScholarPubMed
Submit a response

Comments

No Comments have been published for this article.